119th Congress · introduced in the House · Dec 18, 2025
ACCESS Through OTC Innovation Act
Official title from Congress.gov
Latest action (Dec 18, 2025): Referred to the House Committee on Energy and Commerce.
View on Congress.govPolicy area: Health
No official summary has been published for this bill.
No cosponsors.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
8 citations.
HALEON US HOLDINGS LLC · lobbying firm or registrant: HALEON US HOLDINGS LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$210,000
Spent on own lobbying
…e the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · lobbying firm or registrant: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 13, 2026 · issue area: Health Issues
$146,407
Paid to lobbying firm
…Sunscreen Standards Act H.R.1 - One Big Beautiful Bill Act H.R.5371 - Continuing Appropriations and Extensions Act, 2026 S.2491 - SAFE Sunscreen Standards Act H.R.6868 - ACCESS Through OTC Innovation Act S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescrip…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
HALEON US HOLDINGS LLC · lobbying firm or registrant: HALEON US HOLDINGS LLC
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$260,000
Spent on own lobbying
…e the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act H.R.7366 - Dietary Supplement Regulatory Uniformity Act General monitoring of legislative and administrative action related…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · lobbying firm or registrant: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 14, 2026 · issue area: Health Issues
$199,750
Paid to lobbying firm
…ds Act S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches (SMART OTC Act) H.R.6868 - To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to apply the least burdensome appropriate means for su…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
HALEON US HOLDINGS LLC · lobbying firm or registrant: HALEON US HOLDINGS LLC
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$240,000
Spent on own lobbying
…e the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches. S.3677 - Dietary Supplement Listing Act of 2026 H.R. 6868 - ACCESS Through OTC Innovation Act General monitoring and review of implementation of Title V of H.R.5371 - Continuing Appropriations, Agriculture, Legislativ…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · lobbying firm or registrant: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 14, 2026 · issue area: Health Issues
$159,409
Paid to lobbying firm
…ds Act S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches (SMART OTC Act) H.R.6868 - To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to apply the least burdensome appropriate means for su…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
HALEON US HOLDINGS LLC · lobbying firm or registrant: HALEON US HOLDINGS LLC
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$210,000
Spent on own lobbying
…icular provisions under Title V related to Over-the-Counter Monograph Drug User Fee Amendments. H.R.4273 - Over-the-Counter Monograph Drug User Fee Amendments; H.R.6868 - To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to apply the least burdensome appropriate means for su…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · lobbying firm or registrant: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 14, 2026 · issue area: Health Issues
$245,484
Paid to lobbying firm
…ds Act S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches (SMART OTC Act) H.R.6868 - To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to apply the least burdensome appropriate means for su…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing